Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intelligence Quotient Assessment in Children With Autistic Spectrum Disorders.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04066673
Recruitment Status : Not yet recruiting
First Posted : August 26, 2019
Last Update Posted : August 28, 2019
Sponsor:
Information provided by (Responsible Party):
Asmaa Mohammed Mohammed Tawfeek, Assiut University

Brief Summary:
The aim of this study is to assess the cognitive strengths and weaknesses of children with autism and the possible effect of age and IQ on Stanford-Binet Intelligence Scale, 5th Edition. Such analysis will help us for prompt and early intervention.

Condition or disease Intervention/treatment
Autism Spectrum Disorder Diagnostic Test: Stanford-Binet Intelligence Scale, 5th Edition

Detailed Description:

Autism Spectrum Disorders (ASDs) are characterized by deficits in both social interaction and communication, as well as by restricted and repetitive patterns of behavior, and are a type of Pervasive Developmental Disorder (PDD). Intellectual disability (ID) is characterized by deficits in adaptive functioning, an intelligence quotient (IQ) that falls at least two standard deviations below average (i.e., below 70), and onset prior to adulthood (American Psychiatric Association, 2000).

Although ID is not a core symptom of ASD, there is an established relationship between the two constructs. Seventy percent of children with AD have a co-morbid diagnosis of ID (Bolte & Poustka, 2002; Fombonne, 2005). It has been suggested that many children who would have been diagnosed with ID in the past would today receive an ASD diagnosis, even with identical symptomatology (Lecavalier et al., in press).

The SB5 is a descendent of the very first intelligence measure ever created. It tests general intellectual ability, and the Fifth Edition affords the ability to report Full Scale, Abbreviated, Nonverbal, and Verbal IQ scores(Roid, 2003).. One of the updated features of the SB5 is the nonverbal component, in that close to half of the responses no longer require verbal answers (Coolican, Bryson & Zwaigenbaum, 2008).The Full Scale IQ is derived from the verbal and nonverbal scales, each with five subtests bearing the same names: Fluid Reasoning, Knowledge, Quantitative Reasoning, Visual Spatial Processing, and Working Memory.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 40 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Intelligence Quotient Assessment in Children With Autistic Spectrum Disorders.
Estimated Study Start Date : September 2019
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : October 2020

Resource links provided by the National Library of Medicine



Intervention Details:
  • Diagnostic Test: Stanford-Binet Intelligence Scale, 5th Edition
    The SB5 is a descendent of the very first intelligence measure ever created. It tests general intellectual ability, and the Fifth Edition affords the ability to report Full Scale, Abbreviated, Nonverbal, and Verbal IQ scores


Primary Outcome Measures :
  1. Intelligence Quotient assessment in autistic children by the Stanford-Binet Intelligence Scales, 5th Edition [ Time Frame: Baseline ]
    assess the cognitive strengths and weaknesses of children with autism and the possible effect of age and IQ on Stanford-Binet Intelligence Scale, 5th Edition.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   3 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
Forty children will participate in the study, clinically diagnosed by CARS Scoring IQ will be assessed by Stanford-Binet Intelligence Scales, 5th Edition have autism .They will be recruited from children attending Assiut University Hospital.
Criteria

Inclusion Criteria:

  • Age: from3 to18 years
  • Gender: both sexes will be included in the study
  • Clinical ASD diagnosis.
  • Full Scale test results available for SB5.

Exclusion Criteria:

  • 1- Age below 3years or above 18 years. 2- Mental Retardation due to other causes than autism. 3- Presence of other chronic illnesses affecting their quality of lives.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04066673


Contacts
Layout table for location contacts
Contact: Asmaa Mohammed Mohammed, Resident 01155096915 Asmaa_tawfeek@med.au.edu.eg
Contact: Prof. Mohamed Mahrous EL-Tellawy, Professor of pediatric 01003486595 Fahim.osman@med.au.edu.eg

Sponsors and Collaborators
Assiut University
Publications:
Layout table for additonal information
Responsible Party: Asmaa Mohammed Mohammed Tawfeek, Resident of pediatric Department,, Assiut University
ClinicalTrials.gov Identifier: NCT04066673    
Other Study ID Numbers: IQ in Autism
First Posted: August 26, 2019    Key Record Dates
Last Update Posted: August 28, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Autism Spectrum Disorder
Child Development Disorders, Pervasive
Neurodevelopmental Disorders
Mental Disorders